摘要
自身免疫性脑炎(autoimmune encephalitis,AE)是一类由自身免疫机制介导的中枢神经系统炎性疾病,以抗N-甲基d-天冬氨酸受体(N-methyl-D-aspartate receptor,NMDAR)脑炎最常见。AE治疗分为免疫治疗、对症治疗、支持治疗以及康复治疗。最主要的是免疫治疗,包括一线免疫治疗、二线免疫治疗和长程免疫治疗。一线免疫治疗2周疗效仍欠佳的难治性AE患者需要采取升级免疫治疗或添加免疫治疗。硼替佐米(bortezomib,BTZ)作为一种蛋白酶体抑制剂,在难治性AE中的应用逐渐增多,本文对BTZ应用于难治性AE的国内外研究现状进行综述。
Autoimmune encephalitis(AE)is an autoimmune inflammatory disease affecting the central nervous system,characterized by autoimmune mechanisms.The most prevalent form is encephalitis associated with anti-N-methyl-D-aspartate receptor(NMDAR)antibodies.Treatment for AE can be categorized into immunotherapy,symptomatic management,supportive care,and rehabilitation.Among these,immunotherapy is paramount and it includes first-line,second-line,and long-term approaches.Patients with refractory AE,who show limited improvement even after two weeks of first-line immunotherapy,should be considered for intensified or adjunctive immunotherapy.Bortezomib(BTZ),a proteasome inhibitor,has emerged as a promising treatment option for refractory AE and has been increasingly utilized worldwide.This article provides an overview of the current research on the use of BTZ in refractory AE,both domestically and internationally.
作者
王雯瑾
姚淑美
郭守刚
WANG Wenjin;YAO Shumei;GUO Shougang(Qilu Medical College,Shandong University,Jinan 250012,China;Department of Neurology,Shandong Provincial Hospital Affiliated to Shandong First Medical University,Jinan 250021,China)
出处
《山东第一医科大学（山东省医学科学院）学报》
CAS
2024年第1期45-50,共6页
Journal of Shandong First Medical University ＆ Shandong Academy of Medical Sciences
基金
国家自然科学基金(82072079)。
